EGFR and non-small cell lung carcinoma: Of note, the phase II trial ATLANTIC evaluated the effectiveness of durvalumab in second-line and above treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who had experienced at least two regimens of chemotherapy or EGFR TKIs (93).